EH
CN
Home
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Contact Us
EH
CN
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Home
>
Haisco
>
Historical evolution
>
2016
05月13日
2022-01-07 14:43:50
海思科及下属全资子公司与美国MaveriX Oncology,Inc.公司签署相关协议,对MaveriX进行股权投资,并获得MaveriX全球首创新型肿瘤靶向释放吉西他滨前药MVX系列化合物在中国(包括香港、澳门、台湾地区)的独家专利许可权。
Returns